Abbott reports positive outcomes for structural heart therapies

26 June 2020 (Last Updated June 26th, 2020 10:49)

Abbott has reported late-breaking data on some of its products for the treatment of structural heart diseases.

Abbott reports positive outcomes for structural heart therapies
The data on Abbott’s devices shows continued positive outcomes for less invasive transcatheter therapies. Credit: Abbott.

Abbott has reported late-breaking data on some of its products for the treatment of structural heart diseases.

The data included findings on the MitraClip system for transcatheter mitral valve repair and data on TriClip system for transcatheter tricuspid valve repair and the Tendyne transcatheter mitral valve implantation system.

The data on the devices shows continued positive outcomes for less invasive transcatheter therapies.

According to the company, its MitraClip has shown leading safety and effectiveness in the largest dataset yet.

In four separate analyses of the global EXPAND study, the device consistently achieved considerable mitral regurgitation (MR) reduction in patients with either primary or secondary MR.

The EXPAND study analysed over 1,000 patients who received Abbott’s third-generation device MitraClip NTR/XTR at 57 sites worldwide.

Clinical outcomes for the Tendyne, the company’s transcatheter mitral valve replacement device, indicated long-lasting severe MR symptom relief at two-year follow-up.

The device was analysed in 100 patients with symptomatic, moderate-to-severe or severe MR in an EU Clinical Study.

The study also found that the valve system valve offers a safe treatment option for people with symptomatic MR who are not eligible for open-heart surgery or transcatheter mitral valve repair.

Abbott’s TriClip showed sustained TR reduction in 87.1% of patients who received the device and a low all-cause mortality rate of 7.1% at one year. It also noted the positive impact of right ventricular function with sustained improvements in right heart function.

The company also listed IDE data findings on Amplatzer Amulet Left Atrial Appendage Occluder and the Portico transcatheter aortic valve replacement.

Abbott presented the new late-breaking data on transcatheter structural heart therapies as part of a virtual three-day PCR e-Course held by the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Abbott’s structural heart business senior vice-president Michael Dale said: “At Abbott, we are advancing science and innovative technology to ensure people living with structural heart diseases have safe and effective treatment options.

“The data presented during this year’s PCR underscore our unwavering commitment to solving the health challenges of those managing debilitating heart conditions.”